The story in detail
Viral persistence is one proposed mechanism in long COVID. RECOVER-VITAL tested 15-day and 25-day nirmatrelvir–ritonavir regimens against a control condition in a randomised, blinded trial. The main analysis included 959 adults. At day 90, neither regimen showed significant benefit for the primary cognitive, autonomic or exercise-related symptom outcomes; secondary measures also showed no clear advantage.
A negative trial does not mean long COVID is unreal or that every antiviral approach must fail in every setting. It evaluates these regimens in the populations studied. Treatment during acute infection is a separate question. The findings show why a plausible mechanism needs clinical testing and do not support self-starting a prolonged antiviral course for persistent symptoms.
Study date: 2026-08-31 · Story: 20 October 2026
What was found?
In the RECOVER-VITAL analysis of 959 adults, researchers evaluated fifteen or twenty-five days of nirmatrelvir–ritonavir. At day ninety, neither regimen significantly improved cognitive, autonomic or exercise-related symptom outcomes compared with placebo plus ritonavir.
What does it mean?
A medicine used for acute COVID cannot automatically be assumed effective for persistent symptoms. Other approaches still require controlled investigation.
Limitations
The findings concern these treatment durations and symptom groups. They do not establish that every antiviral approach is ineffective or exclude viral persistence as a possible mechanism.
Sources and review scope
Original article (DOI) · Reviewed source 1 · Reviewed source 2 · Reviewed source 3
Randomized controlled clinical trial; primary abstract checked.
Sources last checked: 20 October 2026.
Editorial expansion: 21.10.2026
Keep this story
Feedback to the editor
Only the editor can read this; it is not a public comment. Do not include personal health information.
Sign in to send feedback